Manpreet Kohli, MD
Surgical Oncology · Long Branch, NJNPI 1205097581
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,500 of the $19,712 with a category attached, or 78.6%. Impedimed, Inc. accounts for 90.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $5,843 and has fallen 55.3% since, to $2,613 in 2025. Among surgical oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $563.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impedimed, Inc.$18K
- Integra Lifesciences Corporation$1K
- Endomagnetics Ltd$208
- Leica Microsystems Inc.$162
- AstraZeneca$125
- Genentech USA, Inc.$70
- plus $86 from 3 others
What the payments were for
- Speaking & faculty fees$15,50079%
- Travel & lodging$100%
- Food & beverage$3,82819%
- Gifts$560%
- Other$3192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impedimed, Inc. | 7 | $17,806 |
| Integra Lifesciences Corporation | 11 | $1,256 |
| Endomagnetics Ltd | 4 | $208 |
| Leica Microsystems Inc. | 2 | $162 |
| AstraZeneca | 1 | $125 |
| Genentech USA, Inc. | 5 | $70 |
| Medtronic | 2 | $46 |
| Cashflow Solutions, LLC | 2 | $27 |
| KCI USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,712 in reported general payments places this provider in the 95th percentile of 59 surgical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 16 | $50 |
| Oxycodone Hcl | 17 | $25 |
| Diazepam | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Long Branch
- Thangamani SeenivasanSomerville$22K
- John CunninghamBerkeley Heights$20K
- Haejin InNew Brunswick$12K
- Anjeanette BrownCape May Court House$11K
- Marc FromerBrick$9K
- Russell LanganLivingston$9K
- Elsa PichardoPlainsboro$8K
- Denise Johnson MillerNeptune$8K
- Donald Mc CainHackensack$7K
- Joseph KimEnglewood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.